Stock MOB MOBERG PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Moberg Pharma AB

Equities

MOB

SE0020353928

Pharmaceuticals

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:44 2024-04-26 am EDT 		5-day change 1st Jan Change
33.16 SEK -2.87% Intraday chart for Moberg Pharma AB +7.94% +118.16%
Apr. 08 Moberg Pharma AB Submits Application to Include an Additional Terbinafine Supplier CI
Feb. 26 Certain Ordinary Shares of Moberg Pharma AB are subject to a Lock-Up Agreement Ending on 26-FEB-2024. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 750 337.9 143.1 236.5 228 425
Enterprise Value (EV) 1 1,234 -546.9 131.2 137.8 108.5 369.2
P/E ratio 37.8 x 0.29 x 23.5 x 31.9 x -11 x -11.4 x
Yield - - - - - -
Capitalization / Revenue 1.71 x 10.9 x 4.25 x - 1,101 x -
EV / Revenue 2.81 x -17.6 x 3.9 x - 524 x -
EV / EBITDA 15 x -66.5 x 13.3 x -6.98 x -5.53 x -13.7 x
EV / FCF -28.4 x - - 3.42 x -1.66 x -2.47 x
FCF Yield -3.52% - - 29.3% -60.1% -40.5%
Price to Book 1.26 x 0.39 x 0.37 x 0.54 x 0.43 x 0.7 x
Nbr of stocks (in thousands) 1,744 1,867 1,986 4,405 9,827 27,961
Reference price 2 430.0 181.0 72.05 53.70 23.20 15.20
Announcement Date 4/16/19 9/27/19 4/19/21 4/19/22 4/18/23 4/12/24
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 439 31.11 33.66 - 0.207 -
EBITDA 1 82.36 8.228 9.883 -19.73 -19.62 -26.96
EBIT 1 48.3 -8.79 9.831 -19.73 -20.52 -27.91
Operating Margin 11% -28.26% 29.21% - -9,911.59% -
Earnings before Tax (EBT) 1 25.85 -10.13 8.955 -19.97 -19.51 -25.42
Net income 1 19.84 1,118 5.865 7.492 -15.71 -21.09
Net margin 4.52% 3,592.74% 17.43% - -7,589.37% -
EPS 2 11.37 626.9 3.067 1.681 -2.100 -1.330
Free Cash Flow 1 -43.41 - - 40.32 -65.28 -149.4
FCF margin -9.89% - - - -31,537.44% -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - 538.19% - -
Dividend per Share - - - - - -
Announcement Date 4/16/19 9/27/19 4/19/21 4/19/22 4/18/23 4/12/24
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 484 - - - - -
Net Cash position 1 - 885 11.9 98.7 119 55.8
Leverage (Debt/EBITDA) 5.874 x - - - - -
Free Cash Flow 1 -43.4 - - 40.3 -65.3 -149
ROE (net income / shareholders' equity) 3.46% - - -3.91% -3.25% -3.69%
ROA (Net income/ Total Assets) 2.44% - - -2.65% -2.53% -2.91%
Assets 1 813.1 - - -283 622 725
Book Value Per Share 2 341.0 465.0 195.0 98.50 54.30 21.80
Cash Flow per Share 2 63.50 381.0 9.710 23.30 12.80 2.170
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 4/16/19 9/27/19 4/19/21 4/19/22 4/18/23 4/12/24
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
MOBERG PHARMA AB Stock Moberg Pharma AB
+118.16% 84.57M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MOB Stock
  4. Financials Moberg Pharma AB